Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study

NCT02279524 is registered in ClinicalTrials.gov with Galmed Research and Development, Ltd. as lead sponsor.

NCT NCT02279524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02279524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study
Lead sponsor
Galmed Research and Development, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 29, 2015
Completion date
May 22, 2018
Enrollment
247 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

fatty liver, liver diseases, liver fibroses, non-alcoholic steatohepatitis